Bedside Snapshot
  • Core Use: Antidote for organophosphate insecticide poisoning and nerve agent exposure; reactivates acetylcholinesterase
  • Key Regimens: Adult IV: 2 g over 15-30 min, then infusion 8-10 mg/kg/h (~500 mg/h); EMS autoinjector: 600 mg IM per kit
  • Critical Timing: Most effective when given early, before enzyme-toxin complex "ages" and becomes irreversible
  • Adjunctive Therapy: Always use WITH atropine (primary life-saving drug) and benzodiazepines for seizures; never delay atropine waiting for pralidoxime
  • Key Dangers: Tachycardia, hypertension, muscle rigidity, transient neuromuscular blockade if pushed too fast; accumulation in renal impairment
Brand & Generic Names
  • Generic Name: Pralidoxime chloride (2-PAM Cl)
  • Brand Names: Protopam, 2-PAM, Pralidoxime Auto-Injector, various generics
Medication Class

Oxime cholinesterase reactivator; antidote for organophosphate and nerve agent poisoning. Acts by cleaving the phosphate-enzyme bond on acetylcholinesterase, restoring enzymatic function.

Pharmacology

Mechanism of Action:

  • Organophosphate insecticides and nerve agents inhibit acetylcholinesterase (AChE) by phosphorylating the active site
  • This causes accumulation of acetylcholine at muscarinic and nicotinic receptors, resulting in cholinergic crisis
  • Pralidoxime is an oxime nucleophile that binds to phosphorylated AChE and cleaves the phosphate-enzyme bond
  • Thereby reactivates AChE and restores its ability to hydrolyze acetylcholine
  • Reactivation most effective before "aging" occurs—time-dependent process where organophosphate-AChE complex becomes resistant to oxime (minutes to hours depending on agent)
  • Limited CNS penetration; key clinical effect is reversing nicotinic neuromuscular junction dysfunction (weakness, fasciculations, paralysis)
  • Improves respiratory muscle function and provides some improvement of muscarinic signs when combined with atropine

Pharmacokinetics:

  • Onset: Clinical improvement in muscle strength and fasciculations may be seen within minutes of IV administration in responsive patients
  • Distribution: Largely extracellular; volume of distribution ~0.6-1.7 L/kg; limited CNS penetration
  • Metabolism: Minimal; most excreted unchanged
  • Elimination: Primarily renal; elimination half-life ~1.5-2 hours; prolonged in renal impairment
  • Repeated boluses or prolonged infusions can lead to accumulation in reduced kidney function; dose reduction recommended in significant renal failure
Indications
  • Confirmed or strongly suspected organophosphate insecticide poisoning with cholinergic signs (SLUDGE/DUMBELS) and/or nicotinic features (fasciculations, weakness, paralysis)
  • Confirmed or suspected nerve agent exposure (sarin, soman, tabun, VX) with cholinergic manifestations; give as early as possible with atropine and benzodiazepines
  • Severe cholinergic crisis from therapeutic/intentional overdose of acetylcholinesterase inhibitors (neostigmine, pyridostigmine) with significant neuromuscular weakness
  • Empiric therapy in undifferentiated cholinergic toxidrome when organophosphate/nerve agent on differential—typically after/alongside atropine and in consultation with toxicology
Dosing & Administration

Available Forms:

  • IV Vials: Commonly 1 g or 2 g pralidoxime chloride powder for reconstitution; typical concentration 50 mg/mL (1000 mg in 20 mL)
  • Premixed IV Bags (institution-specific): e.g., 2 g in 100 mL NS for loading dose; 6 g in 500 mL NS for continuous infusion (~500 mg/h ≈ 42 mL/h)
  • Autoinjectors: Each kit contains 600 mg pralidoxime IM plus 2 mg atropine IM in separate or dual-chamber devices for rapid field administration

Standard Adult Dosing (Always Follow Local Protocol & Toxicology Advice):

Scenario Typical Dose & Route Frequency/Infusion Notes
Organophosphate poisoning – IV loading (ED/ICU) 2 g IV in 100 mL NS over 15-30 min (~25-30 mg/kg) May repeat 1-2 g in 1 hour if weakness persists Start infusion after loading in moderate/severe cases
Organophosphate poisoning – IV continuous infusion 8-10 mg/kg/h (~500-650 mg/h in 70 kg adult) e.g., 6 g in 500 mL NS at ~42-54 mL/h Continue until clinical recovery and off atropine for 12-24 h (often 1-7 days in severe cases)
Alternative intermittent IV regimen 1-2 g IV over 15-30 min Repeat q6-12 h as needed Less favored than continuous infusion; may be used in resource-limited settings
Nerve agent exposure – EMS autoinjectors (adult) 600 mg IM pralidoxime + 2 mg atropine per kit Mild: 1 kit; Moderate: 2 kits; Severe: up to 3 kits total Give with benzodiazepines for seizures; little benefit from >3 pralidoxime injections
Nerve agent/OP poisoning – IV regimen (hospital) 2 g IV over 15-30 min, then 8-10 mg/kg/h infusion Adjust rate to symptoms and renal function Same as OP regimen; early administration critical before aging
Renal impairment Reduce infusion rate (e.g., 25-50% reduction) Monitor for accumulating toxicity No precise regimen; follow tox/nephrology guidance
Pediatrics (outline only) 20-50 mg/kg IV loading (max 2 g), then 10-20 mg/kg/h infusion Adjust per weight and severity Use pediatric-specific protocols and toxicology consultation
Contraindications

Contraindications:

  • Known hypersensitivity to pralidoxime or formulation components
  • Relative: Myasthenia gravis without organophosphate exposure (pralidoxime may transiently worsen weakness by reversing therapeutic cholinesterase inhibition)

Major Precautions:

  • Pralidoxime is adjunctive to atropine, not a substitute: Atropine should be given promptly and titrated to drying of secretions and improved airway resistance
  • Rapid IV push risk: Large doses given rapidly can cause transient neuromuscular blockade, laryngospasm, tachycardia, and hypertension; administer over 15-30 minutes for loading doses
  • Renal impairment: Leads to accumulation; dose reductions and close monitoring for neuromuscular toxicity required
  • Limited CNS penetration: Seizures must be treated with benzodiazepines and standard status epilepticus protocols; pralidoxime will not control seizures
  • Carbamate poisoning: Benefit uncertain; however, often given when exact agent unknown or mixed OP/carbamate exposure possible
Critical Warning: Never delay atropine administration while waiting for pralidoxime. Atropine is the primary life-saving drug for secretions and bronchospasm. Pralidoxime is adjunctive therapy that primarily treats neuromuscular effects.
Adverse Effects

Common:

  • Dizziness, blurred vision, diplopia
  • Headache
  • Nausea, vomiting
  • Tachycardia, transient hypertension
  • Injection-site pain with IM administration

Serious (often dose- or rate-related):

  • Laryngospasm, bronchospasm, or transient apnea with rapid IV administration
  • Neuromuscular blockade with muscle rigidity, weakness, or respiratory arrest (particularly with very high doses)
  • Cardiac arrhythmias, severe hypertension or hypotension in unstable patients
  • Acute worsening of myasthenia gravis symptoms in patients chronically treated with acetylcholinesterase inhibitors
Special Populations

Renal Impairment:

  • Reduce infusion rate by 25-50% in significant renal failure
  • Monitor closely for signs of accumulation (muscle rigidity, weakness, respiratory distress)
  • Follow toxicology and nephrology guidance for specific dosing

Pediatric Patients:

  • Weight-based dosing: 20-50 mg/kg IV loading (max 2 g), then 10-20 mg/kg/h infusion
  • Use pediatric-specific protocols and toxicology consultation
  • Pediatric-specific autoinjectors exist in some systems but less common

Pregnancy/Lactation:

  • Limited data; use only for life-threatening organophosphate/nerve agent poisoning where benefits clearly outweigh risks
  • No adequate controlled studies; decision should involve toxicology consultation
Monitoring

Clinical Monitoring:

  • Airway, breathing, and circulation: ensure adequate oxygenation and ventilation; mechanical ventilation often required in severe cases
  • Continuous ECG and frequent blood pressure monitoring during IV loading and infusion, especially in hemodynamically unstable patients
  • Serial neurologic exams for improvement in muscle fasciculations, strength, and ability to ventilate spontaneously
  • Renal function (serum creatinine, urine output) to guide ongoing dosing, particularly for prolonged infusions

Laboratory Monitoring:

  • Cholinesterase activity levels (plasma or RBC) when available, mainly for trend and occupational health purposes rather than real-time titration
  • Electrolytes, renal function during prolonged therapy
Clinical Pearls
Muscle vs. Airway Agent: Think of pralidoxime primarily as the drug that gives the diaphragm and skeletal muscles back—while atropine is the drug that dries the lungs and saves the airway.
Early Administration Matters: The longer you wait (especially with nerve agents), the more AChE "ages" and becomes resistant to reactivation. When in doubt and exposure is credible, give it.
Continuous Infusion Preferred: Continuous infusion (e.g., 500-650 mg/h in adults) generally provides more stable levels and better outcomes than intermittent boluses in moderate/severe organophosphate poisoning.
Mass-Casualty Events: In nerve agent mass casualties, EMS use of autoinjectors (1-3 kits with pralidoxime + atropine) buys time and should be followed by hospital-based IV infusion regimens.
Toxicology Consultation: Always involve a poison center or medical toxicologist early for dosing nuances, duration of therapy, and transitions off pralidoxime once patient clinically improving.
References
  • 1. Gupta, R., & O'Neil, B. (2023). Pralidoxime. In StatPearls. StatPearls Publishing.
  • 2. Eddleston, M., Buckley, N. A., Eyer, P., & Dawson, A. H. (2008). Management of acute organophosphorus pesticide poisoning. The Lancet, 371(9612), 597-607. https://doi.org/10.1016/S0140-6736(07)61202-1
  • 3. World Health Organization. (2016). Clinical management of acute pesticide intoxication: Prevention of suicidal behaviours.
  • 4. U.S. Department of Health and Human Services. (2017). Nerve agent information for emergency medical services and hospitals. CHEMM.
  • 5. Life in the Fast Lane. (2020). Pralidoxime – Toxicology Library Antidotes. LITFL. https://litfl.com/pralidoxime/
Back to Medication Index
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing and formatting this information. All content is reviewed for accuracy.